Yuko Shimizu

Yuko Shimizu

Auto-generated profile, based on publicly available information

Yuko Shimizu

Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2013 in Journal of Virology
Verified
Journal Article
Open access
PDF file
HNHironori Nishitsuji
Hironori Nishitsuji
KFKenji Funami
Kenji Funami
YSYuko Shimizu
Yuko Shimizu
SUSaneyuki Ujino
Saneyuki Ujino
KSKazuo Sugiyama
Kazuo Sugiyama
KSKunitada Shimotohno
Kunitada Shimotohno
Inflammatory cytokines and chemokines play important roles in inflammation during viral infection. Hepatitis C virus (HCV) is a hepatotropic RNA virus that is closely associated with chronic liver inflammation, fibrosis, and hepatocellular carcinoma. During the progression of HCV-related diseases, hepatic stellate cells (HSCs) contribute to the inflammatory response triggered by HCV infection. However, the underlying molecular mechanisms that mediate HSC-induced chronic inflammation during HCV infection are not fully understood. By coculturing HSCs with HCV-infected hepatocytesin vitro, we found that HSCs stimulated HCV-infected hepatocytes, leading to the expression of proinflammatory cytokines and chemokines such as interleukin-6 (IL-6), IL-8, macrophage inflammatory protein 1α (MIP-1α), and MIP-1β. Moreover, we found that this effect was mediated by IL-1α, which was secreted by HSCs. HCV infection enhanced production of CCAAT/enhancer binding protein (C/EBP) β mRNA, and HSC-dependent IL-1α production contributed to the stimulation of C/EBPβ target cytokines and chemokines in HCV-infected hepatocytes. Consistent with this result, knockdown of mRNA for C/EBPβ in HCV-infected hepatocytes resulted in decreased production of cytokines and chemokines after the addition of HSC conditioned medium. Induction of cytokines and chemokines in hepatocytes by the HSC conditioned medium required a yet to be identified postentry event during productive HCV infection. The cross talk between HSCs and HCV-infected hepatocytes is a key feature of inflammation-mediated, HCV-related diseases.

1 April 2019 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
HSHayato So
Hayato So
RIRyotaro Ikeguchi
Ryotaro Ikeguchi
MKMasaki Kobayashi
Masaki Kobayashi
MSMiki Suzuki
Miki Suzuki
YSYuko Shimizu
Yuko Shimizu
KKKazuo Kitagawa
Kazuo Kitagawa

1 September 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
RIRyotaro Ikeguchi
Ryotaro Ikeguchi
YSYuko Shimizu
Yuko Shimizu
ASAyato Shimomura
Ayato Shimomura
MSMiki Suzuki
Miki Suzuki
KSKanoko Shimoji
Kanoko Shimoji
KKKazuo Kitagawa
Kazuo Kitagawa
Objectives To assess a case of paraneoplastic aquaporin-4 (AQP4)-immunoglobulin G (IgG)–seropositive neuromyelitis optica spectrum disorder (NMOSD) associated with teratoma and determine whether it is a paraneoplastic neurologic disorder. Methods A single case study and literature review of 5 cases. Results A 27-year-old woman presented with diplopia, facial nerve palsy, paraplegia, sensory dysfunction of lower limbs, dysuria, nausea, and vomiting. Spinal cord MRI detected an extensive longitudinal lesion in the spinal cord, and brain MRI detected abnormal lesions in the right cerebral peduncle and tegmentum of the pons. CSF analysis revealed positive oligoclonal IgG bands (OCBs). The patient tested positive for AQP4-IgG, confirming a diagnosis of NMOSD. An abdominal CT scan detected an ovarian tumor. After steroid therapy and tumor removal, the patient progressively improved, with only mild sensory dysfunction. Histopathologic analysis of the tumor revealed a teratoma and the presence of glial fibrillary acidic protein (GFAP)+ neural tissue with AQP4 immunoreactivity, accompanied by lymphocyte infiltration. Including the present case, there have been 6 reported cases of AQP4-IgG–seropositive NMOSD associated with ovarian teratoma (mean onset age, 32.7 years). Of these patients, 5 (83%) presented with nausea and/or vomiting, positive OCB, and dorsal brainstem involvement. Pathologic analyses of the teratoma were available in 5 cases, including the present case, revealing neural tissue with AQP4 immunoreactivity and lymphocyte infiltration in all cases. Conclusions This study suggests that ovarian teratoma may trigger the development of AQP4-IgG–seropositive NMOSD. Further studies are needed to elucidate the pathogenesis of teratoma-associated NMOSD.


10 May 2016 in Clinical and Experimental Neuroimmunology
Verified
Journal Article
Closed access
PDF file
YSYuko Shimizu
Yuko Shimizu
KKKazuo Kitagawa
Kazuo Kitagawa

1 January 2025 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
YSYuko Shimizu
Yuko Shimizu
RIRyotaro Ikeguchi
Ryotaro Ikeguchi
KFKazuo Fujihara
Kazuo Fujihara
KTKenichi Todo
Kenichi Todo
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy characterized by autoantibodies against aquaporin-4 (AQP) that predominantly affecting women of childbearing potential. Unlike multiple sclerosis, NMOSD poses a higher risk of severe and irreversible postpartum relapse, making pregnancy a significant concern in affected women. Historically, in Japan, immunosuppressive treatments were contraindicated in women who could become pregnant, leading many to discontinue therapy before conception. This often resulted in relapse and sometimes required pregnancy termination or abandonment. At present, immunosuppressants such as azathioprine, tacrolimus, and cyclosporine are considered beneficial during pregnancy. Five monoclonal antibody therapies have now been approved and are covered by national insurance for the treatment of NMOSD. These developments have expanded treatment options, enabling safer pregnancies and allowing more women with NMOSD to consider childbirth. To ensure optimal outcomes, individualized, evidence-based treatment plans are essential. Shared decision-making between patients and healthcare providers is critical, particularly when evaluating the safety of monoclonal antibody therapies during pregnancy and their potential impact on fetal development. This review outlines recent insights into the impact of NMOSD on patients of childbearing age, including family planning, postpartum management, and breastfeeding. It emphasizes the importance of balancing disease control with reproductive goals through informed and collaborative care strategies that also encompass AQP4-antibody–negative NMOSD and myelin oligodendrocyte glycoprotein antibody-associated disease.